Contact

First Report Demonstrating The Safety And Immunogenicity Of The SARS-COV-2 BNT162b1 mRNA Vaccine In Younger And Older Chinese Adults: A Randomized, Placebo-Controlled, Observer-Blind Phase I Study

Fengcai Zhu et.al., Research Square (2021) - PMID: n.a.

Product(s) used in this publication: PepMix™ Peptide Pools

Abstract
 

n.a.

Stay in touch and be the first to receive the latest news!